Ascendis Pharma A/S
Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.
$225.25
-$1.37 (-0.60%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-18.92% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 66.5% YoY with margins expanding 57.7pp.
Net debt of €256M represents 5.6x FCF, leverage limits flexibility.
18.2x earnings, 40.9x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1.05B
▲ +66.5% YoY
Net Income (TTM)
€742M
▲ +49.3% YoY
Op. Margin
25.09%
▲ +57.7pp YoY
ROIC
-11.39%
▲ +20.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€335M
▲ +112.4% YoY
Op. Cash Flow (TTM)
€350M
▲ +114.8% YoY
Net Debt
€256M
Cash & Equiv.
€616M
3Y CAGR: +141.4%
Continue Research
Is Ascendis Pharma A/S (ASND) overvalued?
At a P/E of 18.2 and a price-to-free-cash-flow of 40.9, Ascendis Pharma A/S (ASND) trades around a two-stage DCF intrinsic value of about €243.86 per share, so at €225.25 the stock looks around fair value (8.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ascendis Pharma A/S scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Ascendis Pharma A/S's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €243.86 per share for ASND, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €182.89. At today's €225.25, that puts the stock about 8.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Ascendis Pharma A/S a high-quality business?+
Ascendis Pharma A/S scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 25.1% operating margin and a -11.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Ascendis Pharma A/S a good stock to buy right now?+
That depends on valuation and quality together, not either alone. ASND currently trades around its estimated intrinsic value and scores 60/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.